Invion Ltd. · ASX:IVX
Invion — Investor Presentation (September 2013)
25 slides from Invion's investor presentation, September 2013
Slide 1: Invion Limited (ASX:IVX) Corporate Presentation
Invion Limited (ASX:IVX) Clinical-stage life sciences company targeting chronic inflammation Corporate Presentation September | 2013
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Invion Limited (Invion or the Company) solely for its use at presentations to be made by the Company. The information contained in this presentation is an overview and does not contain all information necessary to make investment decisions. Although
Slide 3: Invion proposition
Invion proposition > Two phase II proprietary therapeutic candidates: > INV102 (nadolol) > targeting chronic bronchitis, asthma, cystic fibrosis > INV103 (ala-Cpn10) > targeting lupus > Advancing clinical-stage company with reduced clinical risk > Three FDA-regulated phase II clinical trials current
Slide 4: Management team with proven track record
Management team with proven track record Invion’s management and board have significant experience repurposing drugs for new markets, and guiding drugs through FDA regulatory and approval processes. Greg Collier PhD., Managing Director & Chief Executive Officer > 20 year career in pharmaceutical res
Slide 5: Pipeline: 3 phase II programs, multiple paths to market
Pipeline: 3 phase II programs, multiple paths to market Preclinical Phase I Phase II INV102 (nadolol) Asthma NIH funded, US$4m+ non-dilutive funding (oral delivery) Chronic bronchitis In patients undergoing smoking cessation (oral delivery) Chronic bronchitis Inhaled delivery Cystic fibrosis Inhaled
Slide 6: Assets target large and growing markets
Assets target large and growing markets Respiratory world market $64B Lupus market size ($millions) 4000 Other $20B Asthma $23B 3000 2000 Rhinitis $8B COPD $13B 1000 0 2007 2011 2020 Respiratory market growth drivers Lupus market growth drivers • Improved health economics • Major unmet clinical need
Slide 7: INV102 (nadolol)
INV102 (nadolol) Targeted to treat causes and symptoms of inflammatory lung disease
Slide 8: INV102 (nadolol)
INV102 (nadolol) > Generic drug being repurposed for a new target > Suite of patents granted and in prosecution > Aim to develop an inhaled drug for the treatment of respiratory diseases including asthma and COPD > Short term path to commercialisation with oral treatment > Nadolol is uniquely an inv
Slide 9: Preclinical studies demonstrate airway healing
Preclinical studies demonstrate airway healing Control lung tissue Lung tissue of ‘asthmatic’ mice: epithelial Lung tissue of ‘asthmatic’ mice treated cells have been converted to mucus- with INV102 (nadolol) for 28 days: producing goblet cells. No effect of restored epithelium alprenolol Proof of c
Slide 10: Mechanism of action targets multiple pathways
Mechanism of action targets multiple pathways Mucous plug > Reduction of goblet cell metaplasia > Reduced mucous hypersecretion > Restoration of ciliated epithelium > Reduced levels of pro-inflammatory cytokines: IL-5, IL-10, IL-13 > 50% reduction in eosinophils Healing INV102 > Restoration of lung
Slide 11: Medical, regulatory and commercial precedent
Medical, regulatory and commercial precedent Precedent: Chronic Heart Failure (CHF) FROM TO CONTRAINDICATED STANDARD OF CARE Warning against use of After careful titration, beta blocker beta blockers in CHF for > 25 years. Carvedilol reduced mortality in Carvedilol annual sales (1998) $40m all class
Slide 12: Completed two phase II clinical trials: POC
Completed two phase II clinical trials: POC Objective: Proof-of-concept to evaluate safety and effects on airway with escalating doses administered to 19 subjects with mild asthma Primary endpoint: Objective measure of airway hyper- responsiveness (PC20 MeChFEV1), the diagnostic hallmark of asthma K
Slide 13: INV102: phase II trial design – mild asthma
INV102: phase II trial design – mild asthma Trial name INV102 (nadolol) in mild asthma (NIMA) Trial design Double-blinded, randomised, placebo-controlled, multi-centre Patients 60 subjects (30 subjects in each of two treatment arms) Timing Commenced Q1 2013 Expected completion 2015 Inclusion criteri
Slide 14: INV102: phase II trial design – chronic bronchitis
INV102: phase II trial design – chronic bronchitis Trial name INV102 (nadolol) in smoking cessation of patients with pre-existing COPD Trial design Double-blinded, randomised, placebo-controlled Patients 130 (65 per arm: 54 needed for analysis) Timing Commenced Q3 2013 Initial data Q4 2013 Inclusion
Slide 15: INV102: phase II milestones
INV102: phase II milestones Asthma > NIH funded phase II study ($4M+ non-dilutive funds) commenced Q1 2013 > Initial data on airway histology and sputum biomarkers anticipated Q1 2014 > Complete phase II data anticipated 2015 > Target outcomes: improve airway hyper-responsiveness, reduce airway infl
Slide 16: INV103 (ala-Cpn10)
INV103 (ala-Cpn10) Modified naturally occurring human protein
Slide 17: INV103 (ala-Cpn10)
INV103 (ala-Cpn10) > Modified natural human protein targeting inflammatory disease > Demonstrated anti-inflammatory and immunoregulatory activity in multiple indications > Activity ideally suited to the treatment of inflammation associated with autoimmune disease > Data to date > Dose response reduc
Slide 18: INV103: pre-clinical results in lupus models
INV103: pre-clinical results in lupus models > Strong pre-clinical data in lupus animal model (3 studies) > significantly reduced kidney pathology > improved survival > prevented cutaneous lupus > reduced renal and circulating levels of key pro- inflammatory mediators (TNF-α, IL-6 and MCP-1) reduced
Slide 19: INV103: phase II clinical strategy
INV103: phase II clinical strategy Systemic lupus erythematosus (SLE or lupus) > Lupus is a vascular inflammatory disease > IL-6 is a marker of vascular inflammation > INV103 has a significant effect on IL-6 > Pre-IND meeting with US FDA Q4 2012 > FDA confirmed lupus as important unmet clinical need
Slide 20: INV103: phase II trial design – lupus
INV103: phase II trial design – lupus Trial name INV103 (ala-Cpn10) in mildly active Systemic Lupus Erythematosus (lupus) Trial design Double-blinded, randomized, placebo-controlled, intravenous dosing Patients 32 subjects (8 subjects per dose cohort, 4 cohorts) Timing Commenced Q3 2013 Initial data
Slide 21: INV103: phase II milestones
INV103: phase II milestones Lupus > Q4 2013 completion of 1 or 2 cohorts > biochemical evidence of efficacy; safety of increased doses > driver for scale manufacture of INV103 > driver for clinically outcome-based dose-ranging in lupus > 1H2014: optional: Use higher doses to revisit psoriasis and ot
Slide 22: Summary
Summary 2 drug assets 3 FDA-regulated phase II clinical trials experienced management team significant valuation drivers: 12-36 months
Slide 23: Milestones to watch
Milestones to watch 2013 Q1 Asthma - phase II study in asthma initiated, enrollments and patient dosing underway Q2 Lupus - IND filed with FDA Lupus - commencement of phase II study Q3 Chronic bronchitis (smoking cessation) – commencement of phase II study > Chronic bronchitis - early signal
Slide 24: Corporate snapshot
Corporate snapshot Sector Life Sciences (Biotechnology) Principal activities Clinical-stage pharmaceutical drug development Pipeline 2 drug candidates in 3 phase II clinical programs Operations USA & Australia ASX code IVX Share price (5-Sep-13) $0.085 (8.5 cents) Shares on issue ~463M Options on is
Slide 25: Dr Greg Collier, Managing Director and CEO, Invion Limited
Dr Greg Collier Managing Director and CEO Invion Limited 2/120 Bluestone Circuit Seventeen Mile Rocks QLD 4073 Australia P: +61 7 3295 0500 E: greg.collier@invion.com.au W: www.invion.com.au Corporate Presentation September | 2013